Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Once-a-Day inhaler replace frequent treatments for COPD emergencies?

NCT ID NCT04655170

Disease control Sponsor: University of Tennessee Graduate School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial is testing whether giving long-acting bronchodilators (formoterol and revefenacin) to patients hospitalized with a COPD flare-up can improve breathing as well as or better than the standard short-acting medications (albuterol and ipratropium). The study will compare the two approaches in about 60 adults aged 40 and older who are admitted with a COPD exacerbation. The goal is to see if the long-acting option is feasible, safe, and effective in this setting, potentially simplifying treatment and improving symptom control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Long-acting bronchodilators (formoterol and revefenacin) compared with short-acting bronchodilators (albuterol and ipratropium)
What this could lead to
If effective, this could lead to a more convenient and effective treatment for COPD flare-ups in the hospital, potentially reducing the number of doses needed and improving patient comfort.
What could go wrong
This is a small, early-stage trial (60 patients) that may not show a clear benefit. Long-acting bronchodilators may not be as effective or safe as the standard short-acting drugs in acute hospital settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

60 people

The number who actually took part.

Started

Dec 2020

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or Female 2. Any Race 3. ≥ 40 years of age 4. Admitted to the hospital with a primary diagnosis of AECOPD or acute respiratory failure with a secondary diagnosis of COPD 5. Able to understand and comply with study procedures 6. Willingness to sign and date an Informed Consent Form Exclusion Criteria: 1. Patients unable or unwilling to sign an informed consent or cooperate with study procedures 2. Patients who are hypersensitive to Formoterol or Revefenacin 3. Patients who are intubated, have tracheotomy, are receiving mechanical ventilation by mask or artificial airway 4. Patients, in the opinion of the investigators, who are rapidly decompensating and are immediately in need, or will soon need, ventilator support 5. Patients who, per the investigator, have unstable cardiovascular disease (e.g., uncontrolled, hypertension, unstable angina, recent MI (within 12 weeks), ventricular arrhythmia, or decompensated heart failure) 6. Patients with a current diagnosis of lung cancer requiring treatment 7. Patients that test positive for COVID-19 8. Pulmonary diseases other than COPD, or lobar pneumonia 9. Patients with acute psychiatric illness deemed significant by the investigator 10. Patients with a history of glaucoma deemed significant by the investigator 11. History of urinary retention deemed significant by the investigator 12 Women who are pregnant or breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD exacerbation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD exacerbation

Contacts and locations

Locations

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920-6999, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.